Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression

NCT: NCT03818880 · ACTIVE_NOT_RECRUITING

NCT IDNCT03818880
StatusACTIVE_NOT_RECRUITING
Start Date2018-12-18
Completion2026-12-31

Brief Summary

Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.

Frequently Asked Questions

What is Choroidal Response to Novel Spectacle Lens to Control Myopia Progression?

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression is a clinical trial registered under NCT03818880. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT03818880?

The current status of NCT03818880 (Choroidal Response to Novel Spectacle Lens to Control Myopia Progression) is: ACTIVE_NOT_RECRUITING.

When did Choroidal Response to Novel Spectacle Lens to Control Myopia Progression start?

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression started on 2018-12-18.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑